Eric Bjerkholt

Eric Bjerkholt has served on our Board since April 2023. Bjerkholt has served as the Chief Financial Officer of Mirum Pharmaceuticals, Inc., a publicly traded company, since September 2023.  Mr. Bjerkholt oversees the legal, financial reporting, budgeting, internal controls, investor relations, facilities and information technology functions.  He previously served as the Chier Financial Officer of Chinook Therapeutics, Inc., from November 2020 to September 2023.  Prior to Chinook Therapeutics, Inc., he served as the Chief Financial Officer of Aimmune Therapeutics Inc., from 2017 to 2020. Prior to Aimmune Therapeuticcs, he spent 13 years at Sunesis Pharmaceuticals, Inc. from 2004 to 2017, wher in addition to his role as Chief Financial Officer, Mr. Bjerkholt served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer.  Previously, Mr. Bjerkholt held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc.  He served on the board of directors of Graybug Vision, Inc. (acquired by CalciMedica in 2023), a publicly traded biotechnology company, from 2020 to 2025.  He is currently a member of the board of directs and Chair of the audit committee and a member of the compensation and nominating committees of Metagenomi, Inc., a publicly traded biotechnology company, and a member of the board of directrs and Chair of the audit committee of Cerus Corporation, a publicly traded biotechnology company.  Mr. Bjerkholt holds an M.B.A. from Harvard Business School and a Cand.Oecon from the University of Oslo inn Norway.